Discovery of Rogaratinib (BAY 1163877): a pan‐FGFR Inhibitor
Copyright policy )Discovery of Rogaratinib (BAY 1163877): a pan‐FGFR Inhibitor
AbstractRogaratinib (BAY 1163877) is a highly potent and selective small‐molecule pan‐fibroblast growth factor receptor (FGFR) inhibitor (FGFR1–4) for oral application currently being investigated in phase 1 clinical trials for the treatment of cancer. In this publication, we report its discovery by de novo structure‐based design and medicinal chemistry optimization together with its pharmacokinetic profile.
- Bayer (Germany) Germany
- Bayer Germany
Models, Molecular, Molecular Structure, Thiophenes, Piperazines, Small Molecule Libraries, Drug Discovery, Humans, Pyrroles, Receptor, Fibroblast Growth Factor, Type 1, Protein Kinase Inhibitors
Models, Molecular, Molecular Structure, Thiophenes, Piperazines, Small Molecule Libraries, Drug Discovery, Humans, Pyrroles, Receptor, Fibroblast Growth Factor, Type 1, Protein Kinase Inhibitors
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).49 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Top 10% influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Top 10% impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 1%
Citations provided by BIP!Popularity provided by BIP!